Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 1, 1996, Pages 133-138

  Lin, Pin Fang ^a   Samanta, Himadri ^a   Bechtold, Clifford M ^a   Deminie, Carol A ^a   Patick, Amy K ^a   Alam, Masud ^a   Riccardi, Keith ^a   Rose, Ronald E ^a   White, Richard J ^a   Colonno, Richard J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BMS 186318; CD4 ANTIGEN; GLYCOPROTEIN GP 120; PROTEINASE INHIBITOR; SIAMYCIN I; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CELL; MEMBRANE FUSION; MONKEY; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS ENVELOPE;

EID: 13344277279     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.1.133     Document Type: Article

References (42)

1. Acosta, E. P., and C. V. Fletcher. 1994. Agents for treating human immunodeficiency virus infection. Am, J. Hosp. Pharm. 15:2251-2267.
2. Alam, M., C. M. Bechtold, A. K. Patick, M. T. Skoog, T. G. Gant, R. J. Colonno, A. I. Meyers, H. Li, J. Trimble, and P.-F. Lin. 1993 Substituted naphthalenones as a new structural class of HIV-1 reverse transcriptase inhibitors. Antiviral Res. 22:131-141.
3. n-specific plant lectin from Urlica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Res 18:191-207
4. Barnes, W. M. 1994. PCR amplification of up to 35-Kb DNA with high fidelity and high yield from λ bacteriophage templates. Proc. Natl. Acad. Sci. USA 91:2216-2220.
5. Barrish, J., E. Gordon, M. Alam, P.-F. Lin. G. Bissachi, P. Chen, P. Cheng, A. Fritz, J. Greytok, M. Hermesmeier, W. Humphreys, K. Lis, M. Marella, Z. Merchant, T. Mitt, R. Morrison, M. Obermeier, J. Plusec, M. Skoog, W. Slusarchyk, S. Spergel, J. Stevenson, C.-Q. Sun, J. Sundeen, P. Taunk, J. lino, B. Warrack, R. Colonno, and R. Zahler. 1994 Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR. J Med. Chem 37:1758-1768.
6. Bechtold, C. M., A. K. Patiek, M. Alam, J. Greytok, J. A. Tino, P. Chen, E. Gordon, S. Ahmad, J. C. Barrish, R. Zahler, P.-F. Lin, and R. Colonno. 1995. Antiviral properties of ammodiol inhibitors against human immunodeficiency virus and protease Antimicrob Agents Chemother. 39:374-379.
7. Cao, J., L. Bergeron, E. Helseth, M. Thali, H. Repke, and J. Sodroski. 1993. Effects of ammo acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 67:2747-2755.
8. Constantine, K. L., M. S. Friedrichs, D. Detlefson, M. Nishio, M. Tsunakawa, T. Furumai, H. Ohkuma, T. Oki, S. Hill, R. E. Brucroleri, P.-F. Lin, and L. Mueller. 1994. High resolution structure of BMY-29303: novel amphipathic character of a 21 residue peptide that inhibits HIV fusion. J. Biomol. NMR 5:271-286
9. Cushman, M., P. Wang, J. G. Stowell, D. Schols, and E. De Ciercq. 1992 Structural investigation and anti-HIV activities of high molecular weight ATA polymers. J. Org. Chem. 57:7241-7248
10. De Clercq, E. 1994 Trends in drug development for the treatment of AIDS compounds interfering with the initial stages of the HIV replicative cycle Eur J. Pharm Sci. 2:4-6
11. Detlefson, D., S. Hill, K. Volk, S. Klohr, M. Tsunakawa, T. Oki, P.-F. Lin, and M. Lee. Siamycins I and II. new anti-HIV-1 peptides: sequence analysis and structure determination of stamycin I Submitted for publication.
12. Earl, P. L., and B. Moss. 1993. Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein AIDS Res. Hum Retroviruses 9:589-594
13. Fisher, R. A., J. M. Bertonis, W. Meier, V. A. Johnson, D. S. Costopoulos, T. Liu, R. Tizard, B. D. Walker, M. S. Hirsch, R. T. Schooley, and R. A. Flavell. 1988. HIV infection is blacked in vitro by recombinant soluble CD4. Nature (London) 331:76-78
14. Fréchet, D., J. D. Guitton, F. Herman, D. Faucher, G. Helynck, B. Monegier du Sorbier, J. P. Ridoux, E. James-Surcouf, and M. Vuilhorgne. 1994 Solution structure of RP 71955, a new amino acid tricyclic peptide active against HIV-1 virus. Biochemistry 33:42-50.
15. Helynck, G., C. Duberfret, J.-F. Mayaux, and J. Leboul. 1993 Isolation of RP 71955, a new anti-HIV-1 peptide secondary metabolite. J. Antibiot. 46:1756-1757.
16. Hu, S. L., S. G. Kosowski, and J. M. Dalrymple. 1986. Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature (London) 320: 537-540.
17. Jansen, R. W., G. Molema, R- Pauwels, D. Schols, E. De Clereq, and D. K. F. Merjer. 1991. Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins. Mol. Pharmacol. 39:818-823.
18. Jansen, R. W., D. Schols, R. Pauwels, E. De Clercq, and D. K. F. Meijer. 1993. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol. Pharmacology 44:1003-1007.
19. Japour, A. J., D. L. Mayers, V. A. Johnson, et al. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother 37:1095-1101.
20. Jiang, S., K. Lin, N. Strick, and A. R. Neurath. 1993. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HlV-1 envelope glycoprotein GP41. Biochem. Biophys. Res. Commun. 195:533-538.
21. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66: 2232-2239.
22. Kowalski, M., L. Bergeron, T. Dorman, W. Haseltine, and J. Sodroski. 1991. Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembiane envelope glycoprofein. J Virol. 65: 281-291.
23. Kowalski, M., J. Potz, L. Basiripour, T. Dorfman, W. C. Goh, E. Terwilliger, A. Dayton, C. Rosen, W. Haseltine, and J. Sodroski. 1987. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237:1351-1355.
24. Lee, P. P., and M. L- Linial. 1994 Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 gao is substituted by a myristylation signal J Virol. 68:6644-6654.
25. Lin, P. F., H. Samanta, R. E. Rose, A. K. Patick, J. Trimble, C. M. Bechtold, D. R. Revie, N. C. Khan, M- E. Federici, H. Li, A. Lee, R. E. Anderson, and R. J. Colonno. 1994. Genotypic and phenotypic analysis of human immunodeficiency virus type I isolates from patients on prolonged stavudine therapy. J. Infect. Dis. 170:1157-1164.
26. Maione, R., G. M. Fimia, and P. Amati. 1992. Inhibition of in vitro myogenic differentiation by a polyomavirus early function Oncogene 7:85-93.
27. 7]polyphemusin II) Biochem. Biophys Res. Commun. 189:845-850
28. Mayaux, J.-F., A. Bousseau, R. Pauwels, T. Huet, Y. Henin, N. Dereu, M. Evers, F. Soler, C. Poujade, E. De Clercq, and J.-B. Le Pecq. 1994. Triterpene derivatives that block entry of human immunodeficiency, virus type 1 into cells. Proc. Natl. Acad Sci USA 91:3564-3568
29. Nakashima, H., M. Masuda, T. Murakami, Y. Koyanagi, A. Matsumoto, N. Fujii, and N. Yamamoto. 1992. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22([Tyr-5. 12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion Antimicrob Agents Chemother. 36:1249-1255.
30. Okada, Y. 1993. Sendai virus-induced cell fusion. Methods Enzymol. 221: 18-41.
31. Owens, R. J., C. Burke, and J. K, Rose. 1994. Mutations in the membrane-spanning domain of the human immunodeficiency virus envelope glycoprotein that affect fusion activity. J Virol. 68:570-574.
32. Owens, R. J., C. C. Tanner, M. J. Mulligan, R. V. Srinivas, and R. W. Compans. 1990. Oligopeptide inhibitors of HIV-induced syncytium formation AIDS Res Hum Retrov Retroviruses 6:1289-1295.
33. Patick, A. K., R. Rose, J. Greytok, C. M. Bechtold, M. A. Hermsmeier, P. T. Chen, J. C. Barrish, R. Zahler, R. J. Colonno, and P.-F. Lin. 1995. Characterization ot a human immunodeficiency virus type I variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
34. Pleskoff, O., M. Seman, and M. Alizon. 1995. Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding, effect on virus-cell fusion but not on cell-cell fusion. J. Virol. 69:570-574.
35. Pontecorvo, G. 1975. Production of mammalian somatic cell hybrids by means of polyethylene glycol treatment. Somatic Cell Genet 1:397-400.
36. Potterat, O., H. Stephan, J. W. Metzger, V. Gnau, H. Záhner, and G. Jung. 1994 Aborycin-a tricylic 21-peptide antibiotic isolated from streptomyces griseoflavus. Liebigs Ann. Chem. 1994:741-743.
37. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37: 1207-1213.
38. Takeuchi, H., M. Baba, and S. Shigeta. 1991. An application of tetrazolium (MTT) colorimetric assay for the screening of anti-herpes simplex virus compounds. J Virol. Methods 33:61-71.
39. Tsunakawa, M., Y. Hoshino, T. Furumai, M. Nishio, K. Kawano, S. Yamamoto, Y. Fukagawa, and T. Oki. Siamycins I and II, new anti-HIV peptides. I. Fermentation, isolation, biological activity and initial characterization. Submitted for publication
40. Walker, R. E., R, I. Parjer, J. A. Kovacs, H. Masur, H. C. Lane, S. Carleton, L. E. Kirk, H. R. Gralnick, and A. S. Fauci. 1988. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi's sarcoma treated with zidovudine. Ann. Intern. Med. 108:372-376.
41. Weislow, O. S., R. Riser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586
42. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.